Skip to main content
. 2014 Jun 21;7(4):472–478. doi: 10.1016/j.tranon.2014.05.006

Figure 4.

Figure 4

Response rate of patients treated with TARE and concurrent gemcitabine. Five patients with liver-confined HCC underwent treatment with 200 to 400 mg/m2 gemcitabine 1 day before TARE. One patient was treated to separate lobes of the liver at different times. Shown is the percent change in size of the target lesion based on RECIST.